Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Sulfoxides Stories

2010-02-01 06:00:00

FRAZER, Pa., AESCH, Switzerland, and MAISONS-ALFORT, France, Feb. 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company. Mepha has specific expertise in innovative dosage formulations and markets both generic and branded generic products. The acquisition diversifies the company's business mix, doubles the size of its international...

2010-01-28 07:00:00

FRAZER, Pa., Jan. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced the promotion of three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues. Kevin Buchi is promoted to a new position as Chief Operating Officer with responsibility for Worldwide Pharmaceutical Operations, Worldwide Technical Operations, Investor Relations and Business Development. Mr. Buchi joined Cephalon in 1991 and became Chief Financial Officer (CFO) in 1996. "During his 18...

2010-01-25 07:00:00

NEW YORK, Jan. 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that it recently was advised that its Suzhou Erye Pharmaceutical subsidiary ("Erye") received approval as of November 6, 2009 from the State Food and Drug Administration (SFDA) in China to manufacture and sell omeprazole 20mg capsules. Omeprazole, a proton pump inhibitor (PPI), is the...

2010-01-11 06:30:00

PITTSBURGH, Jan. 11 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Cephalon Inc. and Cephalon France in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg, 150 mg and 250 mg. Armodafinil Tablets are the generic version of Nuvigil(®) Tablets, which are used to improve wakefulness in patients with excessive sleepiness associated with...

2010-01-08 08:00:00

FRAZER, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that effective February 5, 2010, Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical Operations, will resign his position with the company to pursue other longstanding interests. During his tenure, Mr. Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue. The company will announce...

2010-01-06 10:06:00

MORRISTOWN, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents owned by Cephalon France. Watson's...

53e9c84fbe16946afaa08c02bda091c61
2009-12-29 13:26:22

For years, the two most prevalent strategies for treating chronic gastroesophogeal reflux disease "” commonly known as "Ëœacid reflux' "” have been prescription medications and surgery.  Now, after a more than decade-long study in Sweden, researchers say that while both forms of treatment can be successful, each comes with its own unique set of advantages and disadvantages. Acid reflux disease occurs when the acidic digestive fluids in the stomach are regurgitated...

2009-12-21 15:30:00

FRAZER, Pa., Dec. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV]. The sNDA is for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel. "We will continue to work...

2009-12-02 15:05:00

FRAZER, Pa., Dec. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year period of marketing exclusivity for NUVIGIL that extends...

2009-11-23 07:00:00

MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: CEPH) today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms. Analyses of the data indicated...